Why the study?
Do calcium antagonists or ACE inhibitors improve cardiovascular morbidity and mortality compared to beta-blockers and diuretics in hypertensive patients with concomitant risk factors?
Do calcium antagonists or ACE inhibitors improve cardiovascular morbidity and mortality compared to beta-blockers and diuretics in hypertensive patients with concomitant risk factors?
The paper highlights the potential additive benefits of calcium antagonists and ACE inhibitors beyond blood pressure lowering and introduces the INSIGHT trial to evaluate their prognostic influence in high-risk hypertensives.
Answers are grounded in this paper and cite their sources.
Clinical use of calcium antagonists or ACE inhibitors beyond BP lowering remains uncertain; INSIGHT trial results needed to clarify prognostic effects in high-risk hypertension.
BLOOD PRESSURE REDUCTION AND CARDIOVASCULAR MORBIDITY AND MORTALITY: Several hypertension trials have shown that antihypertensive treatment can reduce the cardiovascular morbidity and mortality accompanying this condition. They have also shown, however, that the reduction does not entirely normalize the risk of hypertensive patients. STRATEGIES TO IMPROVE THE BENEFIT OF ANTIHYPERTENSIVE TREATMENT: Although some of the risk of the hypertensive patient may prove to be irreversible, pathophysiological and clinical evidence obtained in recent years suggests that some modifications to antihypertensive treatment strategies might increase the benefit. For example, greater use of drugs such as calcium antagonists and angiotensin converting enzyme (ACE) inhibitors as first-line agents might bring greater benefits, because some properties of these drugs which are additive to their blood pressure lowering effects, such as regression of cardiovascular structural changes, nephroprotection and delay of atherogenesis, may provide a degree of protection against target-organ damage. ONGOING CLINICAL TRIALS AND THE INTERNATIONAL NIFEDIPINE (GITS) GASTROINTESTINAL SYSTEM STUDY OF INTERVENTION AS A GOAL IN HYPERTENSIVE TREATMENT (INSIGHT): Several ongoing clinical trials are aimed at comparing the effects of calcium antagonists and ACE inhibitors versus beta-blockers and diuretics on cardiovascular morbidity and mortality. INSIGHT is particularly interesting because the effects of nifedipine GITS and a combined thiazide and potassium-sparing diuretic on cardiovascular morbidity and fatal events are being compared in patients with hypertension plus one or more additional risk factors, such as hypercholesterolemia, smoking, diabetes, left ventricular hypertrophy, etc. INSIGHT is therefore the first trial to address, in a prospective fashion, the prognostic influence of antihypertensive treatment in hypertensives with concomitant risk factors.
No takes yet. Share an insight, caveat, or question.
Mancia et al. (1996) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: